[ U.S. CDMRP – Autism Research Program Idea Development Award | Research Funding ]
Event details
| Date | 28.04.2020 |
| Category | Call for proposal |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Autism Research Program (ARP) Awards. The ARP Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with ASD.
Important aspects of the ARP Idea Development Award are as follows:
All applications for ARP funding are highly encouraged to address at least one of the FY20 ARP Areas of Interest, which are listed at the end of this announcement.
Funding: max. $550’000
Duration: 3 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Investigators at or above the level of Assistant Professor (or equivalent) are eligible to be named as the Principal Investigator (PI) on the application.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a preproposal narrative, and a list of collaborators and key personnel as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 28-Apr-2020, 5:00 p.m. EST
Full Application Deadline: 28-Jul-2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number: W81XWH-20-ARP-IDA
Further information
FY20 Areas of interest
Important aspects of the ARP Idea Development Award are as follows:
- Impact: The proposed research is expected to make an important and original contribution to advancing the understanding of ASD and ultimately lead to improved outcomes for individuals with ASD and their families/caregivers.
- Innovation: Research deemed innovative may represent a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities
- Personnel: The study team should have experience in ASD research. A biostatistician is encouraged to be included in the study team.
- Research must be based on preliminary data: Although the proposed research must have direct relevance to ASD, the required preliminary data, which may include unpublished results from the laboratory of the Principal Investigators PI(s), research team, or collaborators named on the application, may be from outside the ASD research field.
All applications for ARP funding are highly encouraged to address at least one of the FY20 ARP Areas of Interest, which are listed at the end of this announcement.
Funding: max. $550’000
Duration: 3 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Investigators at or above the level of Assistant Professor (or equivalent) are eligible to be named as the Principal Investigator (PI) on the application.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a preproposal narrative, and a list of collaborators and key personnel as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 28-Apr-2020, 5:00 p.m. EST
Full Application Deadline: 28-Jul-2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number: W81XWH-20-ARP-IDA
Further information
- To see the program announcement, navigate to the search page on Grants.gov and search for the Opportunity Number W81XWH-20-ARP-IDA
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
FY20 Areas of interest
- Tests of implementation strategies to increase use of evidence-based practices
- Development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
- Assessment of novel therapeutics using valid preclinical models
- Mechanisms of heterogeneous clinical expression of ASD
- Environmental risk factors
- Improve diagnosis across the life span
- Factors promoting success in key transitions to independence for individuals living with ASD
- Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services
- Mechanisms underlying sex differences in ASD diagnosis
- Mechanisms underlying conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures)
- Factors impacting quality of life during geographic relocation, such as military permanent change of station
- Long-term treatment outcomes from previous clinical trials for ASD core symptoms or to alleviate co-occurring conditions
Practical information
- General public
- Free